[Current news from the BIKER register]

Z Rheumatol. 2014 Dec;73(10):897-906. doi: 10.1007/s00393-014-1397-9.
[Article in German]


Innovative developments in the pharmacotherapy of juvenile idiopathic arthritis and especially biologics allow the formulation of new therapeutic targets, such as the rapid induction of remission with shortening of the period of active disease and therefore preventing damage and disability. These new therapies also represent a challenge to the monitoring of drug safety, the pharmacovigilance. For this purpose the Society for Paediatric and Adolescent Rheumatology has set up an early register to record achievements in treatment improvement and in addition to independently assess information on drug safety, acute tolerance and long-term safety.

Publication types

  • English Abstract

MeSH terms

  • Adolescent
  • Antibodies, Monoclonal / therapeutic use*
  • Arthritis, Juvenile / drug therapy*
  • Arthritis, Juvenile / epidemiology*
  • Biological Products / therapeutic use*
  • Child
  • Child, Preschool
  • Comorbidity
  • Drug-Related Side Effects and Adverse Reactions / epidemiology*
  • Female
  • Germany
  • Humans
  • Infant
  • Infant, Newborn
  • Male
  • Prevalence
  • Registries / statistics & numerical data*
  • Risk Assessment
  • Treatment Outcome


  • Antibodies, Monoclonal
  • Biological Products